Streptomyces Patents (Class 435/886)
  • Patent number: 4672033
    Abstract: There is presented antibiotic compounds designated as Antibiotics X-14889 A, C and D of the formulas ##STR1## wherein (for X-14889A) R.sub.1 is methyl, R.sub.2 is methyl, R.sub.3 is hydrogen, R.sub.4 is methyl and R.sub.5 is hydrogen or (for X-14889C) R.sub.1 is hydrogen, R.sub.2 is methyl, R.sub.3 is hydrogen, R.sub.4 is methyl and R.sub.5 is CO.sub.2 H or ##STR2## and the pharmaceutically acceptable salts thereof. The compounds exhibit antimicrobial activity and one of the compounds X-14889C also exhibits activity against Treponema hyodysenteriae (in vitro), Plasmodium berghei and as food efficiency enhancers in ruminants.Also presented is a process to produce the above compounds and another known component Antibiotic X-14889B.
    Type: Grant
    Filed: May 23, 1985
    Date of Patent: June 9, 1987
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Chao-Min Liu, John Westley
  • Patent number: 4659660
    Abstract: Antibiotic A47934 is produced by submerged, aerobic fermentation of new Streptomyces toyocaensis NRRL 15009. The antibiotic is active against gram-positive bacteria in vitro and in vivo. It promotes growth in poultry and swine and serves to enhance feed efficiency in ruminant animals having a developed rumen.
    Type: Grant
    Filed: June 3, 1985
    Date of Patent: April 21, 1987
    Assignee: Eli Lilly and Company
    Inventors: Robert L. Hamill, Ralph E. Kastner
  • Patent number: 4657909
    Abstract: Acids, esters, imine acids, imine esters, and imine amides derived from 6-formyl-4,7,9-trihydroxy-1-phenazinecarboxylic acid, methyl ester and from 6-formyl-4,7,9-trihydroxy-8-methyl-1-phenazinecarboxylic acid, methyl ester demonstrate antimicrobial and antineoplastic activity.A purified strain of Streptomyces galanosa, NRRL 15738, is capable of producing 6-formyl-4,7,9-trihydroxy-8-methyl-1-phenazinecarboxylic acid, methyl ester in isolable quantities from a fermentation broth containing assimilable sources of carbon and nitrogen.
    Type: Grant
    Filed: June 10, 1985
    Date of Patent: April 14, 1987
    Assignee: Warner-Lambert Company
    Inventors: Christopher F. Bigge, Edward F. Elslager, James C. French, Blanche D. Graham, Gerard C. Hokanson, Stephen W. Mamber, Tim A. Smitka, Josefino B. Tunac, John H. Wilton
  • Patent number: 4654211
    Abstract: Antibiotic FR-900451 is produced by Streptomyces griseorubiginosus No. 43708 (FERM BP-699).
    Type: Grant
    Filed: November 30, 1984
    Date of Patent: March 31, 1987
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Masami Ezaki, Seiji Hashimoto, Tadaaki Komori, Kazuyoshi Umehara, Masanobu Kohsaka
  • Patent number: 4652523
    Abstract: A new polyether antibiotic has been isolated from fermentations of a new microorganism of the genus Streptomyces. This new microorganism is designated as N478-13 and it has been named Streptomyces routienii Huange sp. nov., (ATCC 30446). The new antibiotic exhibits antibacterial activity against a variety of gram-positive bacteria; it can be used to control swine dysentery; and it promotes increased efficiency of feed utilization (i.e. promotes increased growth) in swine and ruminants.
    Type: Grant
    Filed: October 15, 1984
    Date of Patent: March 24, 1987
    Assignee: Pfizer Inc.
    Inventors: Walter D. Celmer, Walter P. Cullen, Hiroshi Maeda, Junsuke Tone
  • Patent number: 4623626
    Abstract: L-glutamic acid oxidase, which is an L-amino acid oxidase catalyzing the oxidative deamination of the .alpha.-amino group of L-glutamic acid in the presence of water and oxygen to form .alpha.-ketoglutaric acid, ammonia and hydrogen peroxide, and having a very high substrate specificity for L-glutamic acid substantially without acting on L-glutamine and L-histidine, and also having a high stability, and a microbiological method of production thereof.
    Type: Grant
    Filed: June 28, 1983
    Date of Patent: November 18, 1986
    Assignee: Yamasa Shoyu Kabushiki Kaisha
    Inventors: Hitoshi Kusakabe, Yuichiro Midorikawa
  • Patent number: 4612285
    Abstract: A novel antibiotic, awamycin, and its production. Awamycin is active against gram positive bacteria and exhibits growth inhibitory activity against Erhlich ascites and Sarcoma 180 cells. Some of the identifying characteristics of awamycin include a molecular weight of 744.+-.1 (mass spectrum analysis), an elementary analysis of 59.16% C, 6.48% H and 1.88% N; a melting point of 158.degree. C.; an optical rotation of [.alpha.].sub.D 24=+836.degree.. Awamycin is an acidic substance, which provides an orange colored powder, and is poorly soluble in water.
    Type: Grant
    Filed: October 25, 1983
    Date of Patent: September 16, 1986
    Assignee: Kitasato Institute
    Inventors: Iwao Umezawa, Kanki Komiyama
  • Patent number: 4609626
    Abstract: A method for producing S-adenosyl-L-homocysteine hydrolase, which comprises cultivating a microorganism having the ability to produce S-adenosyl-L-homocysteine hydrolase within its cells in a nutrient medium to accumulate said hydrolase in the cells, said microorganism being a bacterium belonging to the genera Alcaligenes, Pseudomonas, Acinetobacter, Arthrobacter, Enterobacter, Rhodopseudomonas, Agrobacterium, Micrococcus, Corynebacterium, Brevibacterium, Chromobacterium, Xanthomonas, Flavobacterium, Cellulomonas, Azotobacter and Protaminobacter, or an actinomycete belonging to the genera Streptomyces, Mycobacterium, Nocardia, Streptoverticillium, Micromonospora, Micropolyspora, Streptosporangium and Microellobosporia; and then recovering S-adenosyl-L-homocysteine hydrolase from the cells.
    Type: Grant
    Filed: July 25, 1984
    Date of Patent: September 2, 1986
    Assignee: Nippon Zeon Co., Ltd.
    Inventors: Hideaki Yamada, Sakayu Shimizu, Shozo Shiozaki
  • Patent number: 4605615
    Abstract: L-glutamic acid oxidase having the following biochemical properties:(a) substrate specificity: L-glutamic acid,(b) enzyme action: catalyzes a reaction which forms one mole of .alpha.-ketoglutaric acid, one mole of ammonia and one mole of hydrogen peroxide from one mole of L-glutamic acid, one mole of oxygen and one mole of water, as follows: ##STR1## This oxidase is produced by culturing microorganisms belonging to genus Streptomyces in a nutrient medium and isolating the thus-produced L-glutamic acid oxidase. Particular microorganisms of genus Streptomyces are sp. A7700 FERM P-6241 (NRRL No. 15267) and sp. 8063 FERM P-6242 (NRRL No. 15268). The oxidase can be used for detecting L-glutamic acid or L-glutamate, in an aqueous sample, because it catalyzes a reaction which forms one mole of .alpha.-ketoglutaric acid, one mole of ammonia and one mole of hydrogen peroxide from one mole of glutamic acid, one mole of oxygen and one mole of water.
    Type: Grant
    Filed: March 2, 1983
    Date of Patent: August 12, 1986
    Assignee: Toyo Jozo Kabushiki Kaisha
    Inventors: Hidehiko Ishikawa, Hideo Misaki, Naoki Muto
  • Patent number: 4601984
    Abstract: There are provided antibiotics X-14873 A, G and H of the formulas ##STR1## wherein for X-14873A, R.sub.1 is CO.sub.2 H and R.sub.2 is ##STR2## for X-14873G, R.sub.1 is hydrogen and R.sub.2 is ##STR3## and for X-14873H, R.sub.1 is hydrogen and R.sub.2 is ##STR4## The compounds exhibit antibiotic activity. Also disclosed is a process to produce the above compounds.
    Type: Grant
    Filed: June 30, 1983
    Date of Patent: July 22, 1986
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Chao-Min Liu, Homer D. Tresner, John Westley
  • Patent number: 4600691
    Abstract: R-(Z)-4-amino-3-chloro-2-pentenedioic acid is a novel antibacterial and isolated from Streptomyces viridogenes MA5450, ATCC 39387.
    Type: Grant
    Filed: April 3, 1985
    Date of Patent: July 15, 1986
    Assignee: Merck & Co., Inc.
    Inventors: Louis Chaiet, Richard L. Monaghan, Sheldon B. Zimmerman, Maria I. M. Fernandez
  • Patent number: 4598089
    Abstract: Novel compounds of the formula ##STR1## wherein A signifies the group ##STR2## or --(CH.sub.2).sub.5 --, which inhibit pancreas lipase and can be used for the control or prevention of obesity and hyperlipaemia, are disclosed. The inventive compounds can be produced by the cultivation of microorganism Streptomyces toxytricini, identified as NRRL 15443.
    Type: Grant
    Filed: June 18, 1984
    Date of Patent: July 1, 1986
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Paul Hadvary, Erich Hochuli, Ernst Kupfer, Hans Lengsfeld, Ernst K. Weibel
  • Patent number: 4595589
    Abstract: The invention relates to a method for preventing fungus diseases in plants grown in, for example, a bed containing peat, by adding to the vegetation or the soil streptomyces griseaviridis stains ATCC 39271, 39272 and 39273. The aqueous suspension preferably contains at least 10.sup.5 spores/ml, and at least 10 ml of the aqueous suspension is spread per one m.sup.2, or the seeds are immersed in the aqueous suspension.
    Type: Grant
    Filed: March 16, 1983
    Date of Patent: June 17, 1986
    Assignee: Kemira Oy
    Inventor: Risto Tahvonen
  • Patent number: 4592999
    Abstract: This invention is to provide a new microbial process for producing daunomycin by a mutant strain belonging to the genus Streptomyces.
    Type: Grant
    Filed: July 18, 1983
    Date of Patent: June 3, 1986
    Assignee: Sanraku Incorporated
    Inventors: Hamao Umezawa, Tomio Takeuchi, Kageaki Kouno, Tomoyuki Ishikura, Akihiro Yoshimoto, Yukio Takatsuki, Hiroyasu Tobe
  • Patent number: 4581360
    Abstract: The invention concerns novel sparsomycin (S.sub.c -R.sub.s) derivatives having superior cytostatic activity compared to sparsomycin itself. Said derivatives contain a lipophilic group R.sup.2, selected from C.sub.2 -C.sub.20 -alkyl, aryl, aralkyl and alkaryl, which is preferably n-octyl or benzyl.
    Type: Grant
    Filed: December 9, 1983
    Date of Patent: April 8, 1986
    Assignee: Stichting Katholieke Universiteit
    Inventors: Henricus C. J. Ottenheijm, Robertus M. J. Liskamp
  • Patent number: 4559301
    Abstract: New macrocin and lactenocin ester derivatives of the formula: ##STR1## wherein R is formyl or hydroxymethyl; R.sup.1 is hydrogen, acetyl or propionyl; R.sup.2 is hydrogen or ##STR2## and R.sup.3 is hydrogen, acetyl, propionyl, n-butyryl or isovaleryl; provided that one of R.sup.1 or R.sup.3 must be other than hydrogen; and the acid addition salts thereof; prepared by bioconversion of macrocin or lactenocin with an acylating enzyme system produced by Streptomyces thermotolerans strains, have improved activity against Mycoplasma species.
    Type: Grant
    Filed: March 3, 1983
    Date of Patent: December 17, 1985
    Assignee: Eli Lilly and Company
    Inventors: Jan R. Turner, Veronica M. Krupinski, David S. Fukuda, Richard H. Baltz
  • Patent number: 4552843
    Abstract: A new acidic polycyclic ether antibiotic, CP-63,517, having the formula: ##STR1## and cationic salts thereof produced by submerged aerobic propagation of Streptomyces endus subsp. aureus, ATCC-39574, a new strain of microorganism isolated from a soil sample in Japan, a process for producing this antibiotic and methods for its use to improve feed utilization, promote growth of cattle and swine and to control coccidiosis.
    Type: Grant
    Filed: February 17, 1984
    Date of Patent: November 12, 1985
    Assignee: Pfizer Inc.
    Inventors: Walter D. Celmer, Walter P. Cullen, Hiroshi Maeda, Junsuke Tone
  • Patent number: 4551430
    Abstract: A mutant Streptomyces thermoviolaceus, NRRL 15615, elaborates a thermostable glucose isomerase in high yield, constitutively. The GI produced shows a negligible loss in activity when heated at 90.degree. C. in high fructose corn syrup for 5 minutes relative to the same treatment at 80.degree. C. The mutant microorganism produces about 1500 units of glucose isomerase per gram of dry weight cells in the absence of xylose.
    Type: Grant
    Filed: October 27, 1983
    Date of Patent: November 5, 1985
    Assignee: UOP Inc.
    Inventor: Edmund W. Hafner
  • Patent number: 4547523
    Abstract: A new polyether antibiotic has been isolated from fermentations of a new microorganism of the genus Streptomyces. This new microorganism is designated as N478-13 and it has ben named Streptomyces routienii Huang sp. nov., (ATCC 39446). The new antibiotic exhibits antibacterial activity against a variety of gram-positive bacteria; it can be used to control swine dysentery; and it promotes increased efficiency of feed utilization (i.e. promotes increased growth) in swine and ruminants.
    Type: Grant
    Filed: November 7, 1983
    Date of Patent: October 15, 1985
    Assignee: Pfizer Inc.
    Inventors: Walter D. Celmer, Walter P. Cullen, Hiroshi Maeda, Junsuke Tone
  • Patent number: 4543334
    Abstract: An antibiotic complex, consisting of one major and two minor components, has been isolated from fermentation of a new Streptomyces culture. The components from the complex are three new macrolides which are active as antibacterial agents against certain gram-negative and gram-positive microorganisms.
    Type: Grant
    Filed: December 16, 1983
    Date of Patent: September 24, 1985
    Assignee: Pfizer Inc.
    Inventors: Walter D. Celmer, Walter P. Cullen, Hiroshi Maeda, Junsuke Tone
  • Patent number: 4540661
    Abstract: Antibiotic U-66,026 is produced in a fermentation under controlled conditions using the microorganism Alcaligenes sp., NRRL B-15269. Enhanced fermentation of titers U-66,026 are obtained when Alcaligenes sp., NRRL B-15269, is cultivated in mixture with Streptomyces plicatus strain 395, NRRL 15273.Antibiotic U-66,026 is a useful antibiotic which has antifungal activity.
    Type: Grant
    Filed: February 24, 1983
    Date of Patent: September 10, 1985
    Assignee: The Upjohn Company
    Inventors: Betty R. Hannon, Fritz Reusser, Lester A. Dolak, Alexander D. Argoudelis, Thomas M. Castle
  • Patent number: 4536476
    Abstract: Cyclase, epimerase and a ring expansion enzyme are isolated separately from a cell free extract of a prokaryotic beta-lactam producing organism to provide three separate and stable enzyme reagents for commercial production of cephalosporins from peptide precursors. Isolation is carried out by using ammonium sulfate, gel filtration and ion exchange chromatography. The enzymes may be immobilized on a suitable support and the production of cephalosporins may be carried out continuously.
    Type: Grant
    Filed: June 27, 1983
    Date of Patent: August 20, 1985
    Assignee: Queen's University at Kingston
    Inventors: Saul Wolfe, Donald Westlake, Susan Jensen
  • Patent number: 4534965
    Abstract: A method and composition is provided to control fungal infection of seeds and seedlings. Certain species of Streptomyces are grown on dried ground shrimp waste preferably suspended in a mineral salts medium. The supernate derived from the culture provides fungal infection control when used as a seed-coating or seed-soaking material. The residue, consisting of unused shrimp waste and a Streptomyces species, also provides protection against fungal infection of plants such as cotton seedlings. The residue is employed as a amendment to the soil in the immediate area of the newly planted seed.
    Type: Grant
    Filed: September 26, 1983
    Date of Patent: August 13, 1985
    Assignee: Chevron Research Company
    Inventors: Lewis R. Brown, Susan Brown-Skrobot
  • Patent number: 4532208
    Abstract: A mutant Streptomyces coelicolor, NRRL 15398, produces glucose isomerase constitutively at a level at least as great as the parent does inductively in common growth media. The isomerase can be effectively used to isomerize glucose to fructose in a continuous process using immobilized enzyme.
    Type: Grant
    Filed: May 5, 1983
    Date of Patent: July 30, 1985
    Assignee: UOP Inc.
    Inventors: Edmund W. Hafner, Denise M. Jackson
  • Patent number: 4526866
    Abstract: A novel enzyme inhibitor of angiotensin I-converting enzyme was produced from an actinomycetes belonging to genus Streptomyces. This enzyme inhibitor is a peptide, and specifically inhibits the angiotensin I-converting enzyme, but does not inhibit thermolycin, pepsin and .alpha.-chymotrypsin.
    Type: Grant
    Filed: April 5, 1983
    Date of Patent: July 2, 1985
    Assignee: Fujizoki Pharmaceutical Co., Ltd.
    Inventors: Yasuji Kido, Tsutomu Yoshida, Toshinari Hamakado, Masami Anno, Takahiro Harada, Yoshinobu Motoki
  • Patent number: 4525458
    Abstract: The invention is to provide a method for the production of sphingomyelinase, by culturing in a medium a sphingomyelinase-producing strain belonging to genus Streptomyces and collecting the resulting sphingomyelinase from the cultured medium. The strain, Streptomyces sp. A 9107, newly separated from a soil, is found preferable for the method of the present invention, and has been deposited as NRRL 15100 and FERM-P 4978.
    Type: Grant
    Filed: September 1, 1982
    Date of Patent: June 25, 1985
    Assignee: Toyo Jozo Company, Ltd.
    Inventors: Shigeyuki Imamura, Hideo Misaki, Naoki Muto
  • Patent number: 4522919
    Abstract: Improved bioconverting strain of Streptomyces thermotolerans useful in preparing tylosin esters and new antibacterial macrocin or lactenocin ester derivatives of the formula: ##STR1## wherein R is formyl or hydroxymethyl; R.sup.1 is hydrogen, acetyl or propionyl; R.sup.2 is hydrogen or ##STR2## and R.sup.3 is hydrogen, acetyl, propionyl, n-butyryl or isovaleryl; provided that one of R.sup.1 or R.sup.3 must be other than hydrogen.
    Type: Grant
    Filed: March 3, 1983
    Date of Patent: June 11, 1985
    Assignee: Eli Lilly and Company
    Inventors: Barbara B. Shreve, Jan R. Turner
  • Patent number: 4508647
    Abstract: A novel antitumor antibiotic designated herein as BBM-2040 is produced by fermentation of Streptomyces sp. strain J576-99 (ATCC 39143). BBM-2040, which may be recovered from the fermentation broth in either a desmethanol (BBM-2040B) or methanol-adduct (BBM-2040A) form, inhibits gram positive and acid-fast bacteria and inhibits the growth of tumors such as P388 leukemia in mice.
    Type: Grant
    Filed: May 10, 1984
    Date of Patent: April 2, 1985
    Assignee: Bristol-Myers Company
    Inventors: Masami Hatori, Hiroaki Ohkuma, Masataka Konishi, Takeo Miyaki, Hiroshi Kawaguchi
  • Patent number: 4504584
    Abstract: The invention relates to a biologically pure culture of new strains of the microorganism Streptomyces which are capable upon fermentation of producing a peptide of pharmacological activity.
    Type: Grant
    Filed: May 19, 1982
    Date of Patent: March 12, 1985
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Yoshihiko Kitaura, Osamu Nakaguchi, Keiji Hemmi, Matsuhiko Aratani, Hidekazu Takeno, Satoshi Okada, Hirokazu Tanaka, Masashi Hashimoto, Yoshio Kuroda, Eiko Iguchi, Masanobu Kohsaka, Hatsuo Aoki, Hiroshi Imanaka
  • Patent number: 4503144
    Abstract: The present invention provides a process for the determination of cholesterol in free or bound form by means of cholesterol oxidase and optionally of cholesterol esterase by measurement of the oxygen consumption, of the hydrogen peroxide formed or of the cholestenone formed, wherein the determination is carried out kinetically with the use of a cholesterol oxidase which has been obtained from a micro-organism of the genus Streptomyces and with the addition of 3,4-dichlorophenol.The present invention also provides a reagent for the kinetic determination of cholesterol, comprising cholesterol oxidase and a system for the determination of hydrogen peroxide or of cholestenone and optionally cholesterol esterase, wherein it additionally contains 3,4-dichlorophenol and the cholesterol oxidase used originates from a micro-organism of the genus Streptomyces.
    Type: Grant
    Filed: December 7, 1981
    Date of Patent: March 5, 1985
    Assignee: Boehringer Mannheim GmbH
    Inventors: Rolf Deeg, Helmut Schlumberger, Joachim Ziegenhorn
  • Patent number: 4503152
    Abstract: An antibiotic substance designated as AM-2604-A is described, and is obtained by cultivating an antibiotic AM-2604-A substance-producing strain belonging to the genus Streptomyces in a nutrient medium and recovering the desired substance from the culture broth.
    Type: Grant
    Filed: January 21, 1983
    Date of Patent: March 5, 1985
    Assignee: The Kitasato Institute
    Inventors: Satoshi Omura, Hideki Shimizu
  • Patent number: 4503155
    Abstract: The present invention discloses multifunctional recombinant DNA cloning vectors for use in Streptomyces, Bacillus, and E. coli. The invention further discloses transformants of the aforementioned vectors.
    Type: Grant
    Filed: February 1, 1982
    Date of Patent: March 5, 1985
    Assignee: Eli Lilly and Company
    Inventors: James R. Miller, Jeffrey T. Fayerman, Steven Kovacevic, Nancy E. Beerman
  • Patent number: 4495286
    Abstract: A biologically pure culture of the microorganism Streptomyces pulveraceus subspecies fostreus ATCC 31906 is provided. Strain 31906 is capable of producing the CL 1565 antibiotic complex in a recoverable quantity upon cultivation in an aqueous nutrient medium containing assimilable sources of nitrogen and carbon. The CL 1565 antibiotic complex includes CL 1565-A, -B and -T sodium salt compounds that in dosage form are useful antibiotics and antitumor agents.
    Type: Grant
    Filed: May 25, 1983
    Date of Patent: January 22, 1985
    Assignee: Warner-Lambert Company
    Inventors: Josefino B. Tunac, William E. Dobson, Blanche D. Graham
  • Patent number: 4480033
    Abstract: Yield of lankacidin antibiotics is enhanced by incorporating cyclodextrin into a culture medium where a microorganism capable of producing lankacidin is cultivated.
    Type: Grant
    Filed: April 6, 1983
    Date of Patent: October 30, 1984
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Takashi Suzuki, Junya Okada, Hidekazu Sawada
  • Patent number: 4473649
    Abstract: Novel antibiotic U-64,864 producible in a fermentation under controlled conditions using a biologically pure culture of the microorganism Streptomyces braegensis Dietz sp.n., NRRL 12567. This antibiotic is active against various Gram-positive bacteria, for example, Staphylococcus aureus, Streptococcus pyogenes and Streptococcus pneumoniae. Thus, antibiotic U-64,864 can be used in various environments to eradicate or control such bacteria.
    Type: Grant
    Filed: September 2, 1982
    Date of Patent: September 25, 1984
    Assignee: The Upjohn Company
    Inventors: Lester A. Dolak, Fritz Reusser, Thomas M. Castle, Betty R. Hannon, Alice L. Laborde, Charles K. Marschke
  • Patent number: 4471052
    Abstract: Chemically simplified versions of intermediates on the identified biosynthetic pathway to daunomycin are bioconverted to active analogues of naturally occurring antibiotics.
    Type: Grant
    Filed: January 18, 1982
    Date of Patent: September 11, 1984
    Assignee: Adria Laboratories, Inc.
    Inventors: Lester A. Mitscher, Daniel Lednicer
  • Patent number: 4468462
    Abstract: The present invention discloses selectable recombinant DNA cloning vectors for use in Streptomyces.
    Type: Grant
    Filed: December 22, 1982
    Date of Patent: August 28, 1984
    Assignee: Eli Lilly and Company
    Inventors: Nancy E. Malin, Jeffrey T. Fayerman, Michael D. Jones, James A. Mabe, Walter M. Nakatsukasa
  • Patent number: 4465771
    Abstract: Enduracidin is produced by cultivating an enduracidin-producing microorganism, which belongs to the genus Streptomyces and which has enduracidin-excreting ability or m-fluoro-DL-tyrosine-resistance or has these two properties, until enduracidin is substantially accumulated in the culture broth, and then recovering the same.
    Type: Grant
    Filed: October 30, 1981
    Date of Patent: August 14, 1984
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Ikuo Nogami, Hideo Shirafuji, Shigeo Matsumura
  • Patent number: 4464467
    Abstract: A novel antitumor antibiotic designated herein as BBM-2040 is produced by fermentation of Streptomyces sp. strain J576-99 (ATCC 39143). BBM-2040, which may be recovered from the fermentation broth in either a desmethanol (BBM-2040B) or methanol-adduct (BBM-2040A) form, inhibits gram-positive and acid-fast bacteria and inhibits the growth of tumors such as P388 leukemia in mice.
    Type: Grant
    Filed: July 26, 1982
    Date of Patent: August 7, 1984
    Assignee: Bristol-Myers Company
    Inventors: Masami Hatori, Hiroaki Ohkuma, Masataka Konishi, Takeo Miyaki, Hiroshi Kawaguchi
  • Patent number: 4464466
    Abstract: Novel and useful ribonucleotides of analogs of the well known antibiotics lincomycin and clindamycin. These ribonucleotides are unexpectedly highly active against Streptococcus hemolyticus and Staphylococcus aureus in vivo.
    Type: Grant
    Filed: February 18, 1983
    Date of Patent: August 7, 1984
    Assignee: The Upjohn Company
    Inventors: Alexander D. Argoudelis, David W. Stroman
  • Patent number: 4463091
    Abstract: A method of producing amylase inhibitor AI-B by cultivating an amylase inhibitor AI-B producing strain which belongs to the genus Streptomyces and isolating the amylase inhibitor AI-B from the culture.
    Type: Grant
    Filed: May 28, 1981
    Date of Patent: July 31, 1984
    Assignee: Fujirebio Kabushiki Kaisha
    Inventors: Takahiro Harada, Eiji Miyagawa, Junko Umemoto, Tsutomu Yoshida, Toshinari Hamakado
  • Patent number: 4461831
    Abstract: Novel antitumor antibiotics designated herein as albacarcins M and V are produced by fermentation of Streptomyces albaduncas strain C-38291 (ATCC 39151). The new antibiotics possess antibacterial activity and also inhibit the growth of mammalian tumors such as P388 leukemia in mice.
    Type: Grant
    Filed: August 16, 1982
    Date of Patent: July 24, 1984
    Assignee: Bristol-Myers Company
    Inventors: James A. Matson, Robert W. Myllymaki, Terrence W. Doyle, James A. Bush
  • Patent number: 4460765
    Abstract: A new compound, named "Griseolic acid", and its salts and can be prepared by the cultivation of Streptomyces griseoaurantiacus SANK 63479 (FERM-P 5223). Griseolic acid and its salts inhibit the activity of the enzyme cyclic adenosine monophosphate phosphodiesterase and, as a result of this, have variety of physiological activities and uses.
    Type: Grant
    Filed: May 12, 1982
    Date of Patent: July 17, 1984
    Assignee: Sankyo Company Limited
    Inventors: Atsushi Naito, Fumio Nakagawa, Takao Okazaki, Akira Terahara, Seigo Iwado, Mitsuo Yamazaki
  • Patent number: 4460689
    Abstract: Disclosed is the novel bacteriophage TG1, TG1 derivatives, and the corresponding genome or nucleic acid components of such bacteriophages and derivatives of such genome, which are useful as DNA cloning vectors into organisms, such as bacteria, for example, Streptomyces cattleya NRRL 8057; portions of such phage genome are additionally useful as adjuncts in recombinant DNA cloning procedures, for example: (1) to permit the maintenance of cloned DNA in the host, either in an integrated state or as an autonomous element; (2) to serve as promoters for increasing expression of endogenous or foreign genes wherein said promoters are ligated to such genes or otherwise serve as promoters; and (3) to serve as regulatory elements for achieving control over endogenous and foreign gene expression; as cloning vectors, TG1, its deletion mutants, and other derivatives serve for the amplification and transfer of DNA sequences (genes) coding for useful functions, for example, genes necessary for the production of the antibioti
    Type: Grant
    Filed: March 8, 1983
    Date of Patent: July 17, 1984
    Assignee: Merck & Co., Inc.
    Inventors: Forrest Foor, Nancy R. Morin
  • Patent number: 4456686
    Abstract: A new antibiotic having .beta.-lactamase inhibitory activity, PA-39504-X.sub.1 of the formula: ##STR1## being useful as a medicament and a veterinary drug for inhibiting the growth of gram-positive and gram-negative pathogenic microorganisms and a process for preparing the same, being characterized by cultivating Streptomyces argenteolus PA-39504 or Streptomyces tokunonensis PA-31088 in a suitable medium and recovering PA-39504-X.sub.1 from the cultured broth.
    Type: Grant
    Filed: September 22, 1982
    Date of Patent: June 26, 1984
    Assignee: Shionogi & Co., Ltd.
    Inventors: Kentaro Tanaka, Eiji Kondo, Kouichi Matsumoto, Jun'ichi Shoji, Naoki Tsuji
  • Patent number: 4454228
    Abstract: Novel antibiotic U-64,815 producible in a fermentation under controlled conditions using a biologically pure culture of the microorganism Streptomyces microspinus, NRRL 12524. This antibiotic is active against various Gram-positive bacteria, for example, Staphylococcus aureus. It is also active against Haemophilus influenzae. Thus, antibiotic U-64,815 can be used in various environments to eradicate or control such bacteria.
    Type: Grant
    Filed: September 29, 1982
    Date of Patent: June 12, 1984
    Assignee: The Upjohn Company
    Inventors: Howard A. Whaley, William C. Snyder, John C. Greenfield, John H. Coats
  • Patent number: 4447533
    Abstract: There is presented an antibiotic compound of the formula ##STR1## and the pharmaceutically acceptable salts and esters thereof. The compound exhibits activity as an anti-swine dysentery agent and an antimicrobial agent.Also presented is a fermentation process to produce the compound of formula I.
    Type: Grant
    Filed: July 30, 1982
    Date of Patent: May 8, 1984
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Chao-Min Liu, Homer D. Tresner, John Westley
  • Patent number: 4438201
    Abstract: A novel enzyme, amidohydrolase, having the ability to depantothenylate antibiotic OA-6129A represented by the following formula ##STR1## but no substantial ability to deacetylate antibiotic PS-5 represented by the following formula ##STR2##
    Type: Grant
    Filed: July 1, 1982
    Date of Patent: March 20, 1984
    Assignee: Sanraku-Ocean Co., Ltd.
    Inventors: Katsuro Kubo, Yasuo Fukagawa, Tomoyuki Ishikura
  • Patent number: 4429042
    Abstract: Novel compounds are produced by the fermentation of a nutrient medium with the previously undescribed microorganism Streptomyces avermitilis. They may be isolated by solvent extraction and chromatographic fractionation techniques. The compounds, which are described generically as C-076 have significant parasiticidal activity. The compounds may be included in compositions for the oral or parenteral administration to animals for the prevention and cure of parasitic infections.
    Type: Grant
    Filed: December 30, 1981
    Date of Patent: January 31, 1984
    Assignee: Merck & Co., Inc.
    Inventors: George Albers-Schonberg, Hyman Wallick, Robert E. Ormond, Thomas W. Miller, Richard W. Burg
  • Patent number: RE32333
    Abstract: Antibiotic A-21978 complexes, in particular the A-21978C complex, comprising microbiologically active, related factors C.sub.0, C.sub.1, C.sub.2, C.sub.3, C.sub.4, and C.sub.5. A-21978 complex and A-21978C complex are produced by submerged aerobic fermentation of Streptomyces roseosporus NRRL 11379. The individual A-29178C factors are separated and isolated by chromatography. The A-21978 and A-21978C complexes; the A-21978C factors; and pharmaceutically acceptable salts thereof are antibacterial agents and improve growth promotion in poultry.
    Type: Grant
    Filed: September 26, 1985
    Date of Patent: January 20, 1987
    Assignee: Eli Lilly and Company
    Inventors: Robert L. Hamill, Marvin M. Hoehn